- Few papers suggested that viral replication in vitro was diminished by chloroquine, but those were only laboratory studies. It has not been supported by animal studies;
- Antimalarial drugs such as chloroquine and its derivatives are associated with significant adverse effects;
- Particularly in times of restricted supplies, unjustified and/or overuse can cause drug shortages for those in real need;
- For pediatric patients, Canadian Paediatric Society does not recommend using these drugs to treat suspected or confirmed COVID-19, however, those already under antimalarial should pursue their treatments with a close follow-up.
These recommendations were proposed in an editorial published on the Canadian Paediatric Society based on an in vitro study conducted in China. Further studies are required to assess role, safety and right dosage of chloroquine and its derivatives in both adult and pediatric population.
Michael J Rieder. (March 27, 2020). Chloroquine and COVID-19 in children. Canadian Paediatric Society. https://www.cps.ca/en/blog-blogue/chloroquine-and-covid-19-in-children